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Tissue kallikrein is the main kinin-forming enzyme in
mammals, and differences in kinin levels are thought to be a
contributing factor to diabetic nephropathy. Here, we
determined the role of the kallikrein-kinin system in the
pathogenesis of streptozotocin-induced diabetic
nephropathy in wild-type and tissue kallikrein–knockout
mice. All diabetic mice developed similar hyperglycemia, but
the knockout mice had a significant two-fold increase in
albuminuria compared to the wild-type mice before and after
blood pressure elevation. Ezrin mRNA, a podocyte protein
potentially implicated in albuminuria, was downregulated in
the kidney of knockout mice. One month after induction of
diabetes, the mRNAs of kininogen, tissue kallikrein, kinin B1,
and B2 receptors were all increased up to two-fold in the
kidney in both genotypes. Diabetes caused a 50% decrease in
renal angiotensin-converting enzyme expression and a 20-
fold increase in kidney injury molecule-1 reflecting tubular
dysfunction, but there was no genotype difference. Our study
found an early activation of the kallikrein-kinin system in the
kidney and that this has a protective role against the
development of diabetic nephropathy. The effect of tissue
kallikrein deficiency on microalbuminuria in diabetic mice is
similar to the effect of genetically high angiotensin-
converting enzyme levels, suggesting that both observations,
in part, result from a deficiency in kinins.
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Diabetic nephropathy is one major complication of diabetes.
It is a leading cause of chronic and end-stage renal failure
and is epidemic worldwide. Renal involvement in type 1
diabetes has been linked to increased cardiovascular and renal
morbidity and reduced life expectancy. Elevated micro-
albuminuria, the first clinical hallmark and initial event of
diabetic nephropathy, is a risk factor for established nephro-
pathy and subsequent renal insufficiency in diabetic patients,
and is also an independent risk factor for cardiovascular
disease. It is therefore of potential clinical interest to study the
factors involved in the early phase of diabetic nephropathy and
in the development of albuminuria.
Renal injury is causally linked to chronic hyperglycemia
but additional factors modulate individual patient’s risk of
diabetic nephropathy. Family studies have demonstrated
that genetic factors contribute to the development of dia-
betic renal and vascular complications.1,2 The angiotensin
I–converting enzyme (ACE) gene was one of the first genes
demonstrated to contribute to the risk of diabetic nephro-
pathy. ACE levels are genetically determined, and associated
with genomic polymorphism of the ACE gene.3–5 As the
initial reports showing an association between the genetic
polymorphism of ACE level and diabetic nephropathy,6–8
several major studies have shown that genetic variations of
ACE influence the renal prognosis in type 1 diabetic
patients.9–11 Moreover, a causal link has been established
between genetically high ACE level and severity of kidney
malfunction in diabetic mice.12
Angiotensin I-converting enzyme not only converts angio-
tensin I into angiotensin II, but it is also a major kinin-
degrading enzyme. Computer simulations and experimental
data suggest that a modest increase in ACE level causes a
significant decrease in kinins, while having only limited effect
on systemic angiotensin II production.13,14 Kinins are potent
renal vasodilators and have also antithrombotic and
antifibrotic actions. These findings suggest that kinin levels
may be involved in the genetic determinism of diabetic
nephropathy, and that kinins provide protection against
diabetes-related renal and vascular damage. Kinins exert their
biological effects by stimulation of B1 and B2 receptors. In
diabetes mellitus, increase in gene expression of both
receptors has been observed in microvessels and kidney.15–18
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However, conflicting data have been reported regarding the
contribution of the B2 receptor18–22 and limited information is
available concerning the B1 receptor.23 It is well established
that the B1 receptor is able to take over functions of B2
receptor, making interpretation of studies based on single
inhibition or deficiency difficult.24,25
Tissue kallikrein is the main kinin-forming enzyme in
mammals. We used tissue kallikrein–deficient (TK-null)
mice,26 in which B1 and B2 receptors cannot be activated
due to lack of the endogenous ligand bradykinin, to
document the role of the kallikrein–kinin system (KKS) in
the initiating stages of diabetic nephropathy. We induced
type 1 diabetes in mice, and then compared kidney function
and morphology, and gene expression of components of the
KKS of TK-null mice and wild-type (WT) littermates.
RESULTS
Tissue kallikrein protects against microalbuminuria
Physiological data obtained in series A and B, 1 and 2 months
after the diabetes induction, respectively, are shown in Tables
1 and 2, and Figure 1. Urinary kallikrein activity was
undetectable in TK-null mice. In each series, both the WT
and TK-null diabetic mice developed similar hyperglycemia.
Blood b-hydroxybutyrate concentrations were low
(0–0.6mM), no ketones were found in the urine, and the
urinary pH was the same in all the groups (pHE6.2).
Diabetes-induced changes in fluid intake, urine flow rate, and
glycosuria were not altered by genotype. Genotype did not
influence glomerular filtration rate, and the extent of
hyperfiltration observed at 1 month, followed by return to
normal values at 2 months. However, albumin excretion rate
was significantly increased by diabetes (Po0.0001), and it
was more than twofold higher in TK-null than in WT mice
1 month after diabetes induction (genotype–diabetes inter-
action, P¼ 0.02) (Table 1). In the second series of diabetic
mice studied longer (series B), similar genotype effect
was observed (Figure 1) (genotype–diabetes interaction at 1
month and 2 months, P¼ 0.03 and 0.01, respectively) and
albuminuria increased more rapidly in TK-null than in WT
mice. Similar results were found when urinary albumin
excretion was expressed as albumin/creatinine ratio (Table 2).
Morphological analysis
Diabetes induced similar increase in kidney weight in
TK-null and WT mice (Tables 1 and 2). Light microscopy
observations revealed glomerular hypertrophy (P¼ 0.0012 at
1 month (not shown) and P¼ 0.0028 at 2 months (Table 2))
without overt glomerulosclerosis in the diabetic mice and
only slight and sporadic interstitial fibrosis and tubular
atrophy at 2 months. Diabetes significantly increased the total
glomerular surface area and the surface area of the
glomerular tuft surface without genotype effect (Table 2).
Mesangial morphology was not altered but diabetes induced
an increase in the surface area of Bowman’s capsule, which
was more marked in TK-null than in WT mice. Electron
microscopy showed no gross abnormalities in podocytes of
the kidneys from diabetic mice except few foot process
fusion/effacement at 2 months, endothelial fenestrations and
glomerular basement membranes appeared similar to those
of controls (not shown).
Tissue kallikrein deficiency has no effect on blood pressure
In control conditions, TK-null and WT mice had similar
blood pressure measured by tail-cuff method as previously
reported.27 Blood pressure was not modified in the very early
phase of the diabetes but increased later (Figure 2), with no
interaction between diabetes and genotype. In other groups
of freely moving mice with a telemetric implant, blood
pressure was higher during active than rest period
(þ 12mmHg), there was again no effect of diabetes or
genotype up to 1 month after diabetes induction (not shown)
(implants for telemetric measurement could not be kept
functional in diabetic mice for a longer period).
Tissue-specific effect of diabetes on the expression of the
kallikrein–kinin and renin–angiotensin system genes
The levels of mRNA for components of the renal KKS
1 month after inducing diabetes are shown in Figure 3.
Diabetes significantly increased levels of mRNA for kinino-
gen, TK, and B1-R and B2-R (analysis of variance, Pp0.02).
Renal levels of ACE were significantly decreased in diabetic
mice (Figure 4). The components of renin–angiotensin
system were also affected by diabetes (Figure 5). The
angiotensinogen mRNA levels were increased, whereas the
AT1-R and AT2-R mRNA levels were significantly decreased
(analysis of variance, Pp0.01). No genotype effect was
observed for any of these parameters, except for diabetes-
induced changes in the B2-R and AT2-R mRNA abundance,
which were more marked in TK-null mice. TK deficiency did
not alter the basal expression of KKS and renin–angiotensin
system, except TK of course, renin, and AT2-R in the kidney.
In the lung, the level of ACE mRNA was markedly enhanced
by diabetes (Figure 4). In the liver, diabetes induced an
increase in the abundance of the mRNA of kininogen and
angiotensinogen (Figure 6). Gene expression of most of the
components of the KKS and renin–angiotensin system, except
for ACE, AT1-R, and angiotensinogen, were very low in the
heart. Only the angiotensinogen mRNA level was affected by
genotype (P¼ 0.03) and diabetes (P¼ 0.004) (1.00±0.12,
0.73±0.08, 2.53±0.63, 1.25±0.09, in WT CONT (control),
WT DIAB (diabetic), TK-null CONT, and TK-null DIAB,
respectively). Similar results for KKS and renin–angiotensin
system components were obtained in mice studied at
2 months (Table 3), except for pulmonary ACE and renal
TK that were not significantly different between control and
diabetic mice at this time point.
Expression of two genes expressed in podocytes and
potentially involved in albuminuria was studied. Expression
of the nephrin gene was not affected by genotype or diabetes.
The level of ezrin mRNA was lower in TK-null mice
(genotype effect, Po0.05), and was increased by diabetes at
1 month (Po0.01) (WT CONT: 1.00±0.10, WT DIAB:
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1.43±0.08, TK-null CONT: 0.76±0.02, TK-null DIAB:
1.16±0.11) but the diabetes effect disappeared at 2 months
(WT CONT: 1.00±0.07, WT DIAB: 1.02±0.07, TK-null
CONT: 0.69±0.06, TK-null DIAB: 0.79±0.04). We observed
that gene expression of kidney injury molecule-1, a protein
known to be induced in the proximal tubule during acute
Table 1 | Physiological parameters and kidney weight 1 month after induction of diabetes (series A)
Wild-type TK-null ANOVA (P-value)
CONT DIAB CONT DIAB Genotype Diabetes
Body weight (g) 21.9±0.3 19.3±0.9*** 21.1±0.3 18.9±0.5*** 0.30 o0.0001
Water intake (ml/24 h) 5.44±0.21 27.50±1.95*** 4.53±0.32 26.59±1.32*** 0.39 o0.0001
Food intake (g/24 h) 3.17±0.14 5.54±0.17*** 2.97±0.16 5.33±0.14*** 0.25 o0.0001
Urine flow rate (ml/24 h) 0.98±0.07 21.76±2.36*** 0.87±0.08 23.02±1.11*** 0.55 o0.0001
Urine osmolality (mosm/kg H2O) 3096±146 996±34*** 3501±202 972±49*** 0.24 o0.0001
Urine excretion
Glucose (mmol/24 h) 2.82±0.22 10942±933*** 5.96±2.32 10221±594*** 0.44 o0.0001
Sodium (mmol/24 h) 129±10 521±48*** 118±12 600±31*** 0.20 o0.0001
Potassium (mmol/24 h) 253±26 1096±34*** 221±31 874±29*** 0.0005 o0.0001
Urea (mmol/24 h) 1933±128 4955±332*** 1700±124 4673±271*** 0.26 o0.0001
Kallikrein activity (pKat/24 h) 844±92 932±128 11±4 5±2 0.49 o0.0001
Albumin (mg/24 h) 4.0±1.0 21.7±2.3*** 5.7±0.8 54.6±9.2***,## o0.0001 0.0123
Hematocrit, % 45.1±1.1 44.5±1.9 44.6±1.0 44.9±0.8 0.99 0.93
Blood glucose (mg per 100ml) 125±6 459±39*** 110±4 459±26*** 0.72 o0.0001
Plasma sodium (mmol/l) 143±1 141±0 145±1 145±1 0.009 0.33
Plasma potassium (mmol/l) 5.1±0.2 5.2±0.1 4.9±0.1 4.6±0.2 0.08 0.76
Plasma creatinine (mmol/l) 11.1±1.1 13.7±1.8 10.9±0.5 17.1±2.3* 0.36 0.02
Creatinine clearance (ml/24 h) 252±30 341±30* 209±18 291±37* 0.18 0.019
Kidney weight
Absolute (mg) 255±11 287±14*** 240±10 298±10*** 0.82 0.0005
Relative (mg/10 g body weight) 115±5 150±7*** 107±3 157±6*** 0.96 o0.0001
ANOVA, analysis of variance; CONT, control groups; DIAB, diabetic groups; TK-null, tissue kallikrein–deficient mice.
Results are means±s.e.m., n=10–12/group.
Fisher post hoc test: DIAB vs CONT, *Po0.05, ***Po0.0001; TK-null vs wild type: ##Po0.01.
Table 2 | Physiological parameters and renal morphometric data 2 months after induction of diabetes (series B)
Wild-type TK-null ANOVA (P-value)
CONT DIAB CONT DIAB Genotype Diabetes
Body weight (g) 22.6±0.3 17.1±0.6*** 22.8±0.7 18.2±0.7*** 0.27 o0.0001
Water intake (ml/24 h) 7.70±0.37 23.23±2.63*** 5.95±1.20 21.68±1.74*** 0.35 o0.0001
Food intake (g/24 h) 2.69±0.25 4.74±0.39*** 2.84±0.25 4.53±0.38*** 0.93 o0.0001
Urine flow rate (ml/24 h) 0.72±0.11 17.54±1.21*** 0.72±0.11 15.54±1.76*** 0.32 o0.0001
Urine osmolality (mosm.kg/H2O) 2544±202 990±20*** 2494±172 1008±55*** 0.91 o0.0001
Urine excretion o0.0001
Glucose (mmol/24 h) 2.07±0.45 11578±922*** 2.50±0.47 9259±0.26 o0.0001
Urea (mmol/24h) 933±113 2841±178*** 909±89 2659±238*** 0.53 Po0.0001
Kallikrein activity (pKat/24 h) 307±93 289±64 3±2## 0±0## Po0.0001 0.85
Albumin (mg alb/mmol creat) 3.70±0.70 7.41±0.70** 3.95±0.50 16.00±3.57**,# 0.0225 0.0002
Blood glucose (mg per 100ml) 131±8 545±34*** 127±11 589±11*** 0.33 Po0.0001
Plasma creatinine (mmol/l) 11.9±1.0 17.8±0.9** 13.7±0.6 15.0±1.7 0.66 0.0027
Creatinine clearance (ml/24h) 316±46 273±19 252±24 330±50 0.64 0.92
Kidney weight
Absolute (mg) 239±10 319±12*** 249±8 341±13*** 0.11 o0.0001
Relative (mg/10 g body weight) 104±4 185±10*** 109±3 181±6*** 0.96 o0.0001
Glomerular surface area (mm2) 4543±245 5096±103** 4523±133 5267±187** 0.79 0.0028
Glomerular tuft surface area (mm2) 3149±143 3489±64** 2991±56 3526±155** 0.60 0.034
Bowman’s capsule surface area (mm2) 398±10 416±14 347±10 429±8** 0.13 0.0004
ANOVA, analysis of variance; CONT, control groups; DIAB, diabetic groups; TK-null, tissue kallikrein–deficient mice.
Results are means±s.e.m., n=7–8/group.
Fisher post hoc test: DIAB vs CONT, **Po0.01, ***Po0.0001; TK-null vs wild type, #Po0.05, ##Po0.0001.
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kidney injury, is markedly increased by diabetes at 1- and
2 months (20- and 60-fold, respectively) with no effect of
genotype.
DISCUSSION
In addition to being the earliest clinical manifestation of
nephropathy, albuminuria is an independent risk factor and a
marker for renal as well as cardiovascular disease for type 1 or
type 2 diabetic patients. The level of albuminuria proved to
be one of the major factors that predict renal outcome. The
main finding of our study is that diabetic mice with
inactivation of the TK gene displayed a higher albumin
excretion rate after diabetes induction compared with
diabetic WT mice. The effect of TK deficiency on micro-
albuminuria was observed as early as 1 month after diabetes
induction, and not linked to blood pressure which remains
normal at that stage. At 2 months, in the presence of
hypertension, urinary albumin excretion was still elevated
in TK-deficient mice, whereas blood pressure was not
influenced by this deficiency. This suggests a direct effect of
TK at the glomerular or tubular levels. The finding of
increased urinary albumin excretion in TK-deficient mice
together with the observation of increased gene expression of
TK and other KKS components in the kidney after induction
of diabetes, strongly suggests that TK protects against kidney
dysfunction caused by diabetes mellitus.
In contrast to its effect on albuminuria, TK deficiency did
not influence the hyperfiltration and kidney hypertrophy
induced by diabetes. This confirms that hyperfiltration is
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Figure 1 |Urinary albumin excretion in wild-type (WT) and
tissue kallikrein–deficient (TK-null) mice 1 and 2 months after
induction of diabetes (series B). Black bars: diabetic groups,
white bars: control groups. Results are means±s.e.m. n¼ 7–8/
group. Analysis of variance followed by Fisher PLSD post hoc test,
diabetic vs control: ***Po0.001; TK-null vs WT: ##Po0.01.
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Figure 2 | Systolic blood pressure in wild-type (WT) and tissue
kallikrein–deficient (TK-null) mice 1 and 2 months after
induction of diabetes (series B). Black bars: diabetic groups,
white bars: control groups. Results are means±s.e.m. n¼ 7–8/
group. Analysis of variance followed by Fisher PLSD post hoc test,
diabetic vs control: ***Po0.001, TK-null vs WT: nonsignificant.
0.0
0.5
1.0
1.5
2.0
2.5
TK-nullWT
Tissue kallikrein
***
TK-nullWT
0.5
1.0
1.5
2.0
2.5
Kininogen
** **
R
el
a
tiv
e
 m
R
N
A 
e
xp
re
ss
io
n
B2-R
TK-nullWT
0.0
0.5
1.0
1.5
2.0
2.5
3.0
**
TK-nullWT
0.0
0.5
1.0
1.5
2.0
2.5
3.0
B1-R
***
***
R
el
a
tiv
e
 
m
R
N
A 
e
xp
re
ss
io
n
0.0
Figure 3 |Gene expression of the components of the renal
kallikrein–kinin system in wild-type (WT) and tissue
kallikrein–deficient (TK-null) mice 1 month after induction of
diabetes (series A). Black bars: diabetic groups, white bars:
control groups. Results are means±s.e.m. n¼ 10–12/group.
Results for each gene are expressed relative to the mean of the
corresponding WT control group. Analysis of variance followed by
Fisher PLSD post hoc test, diabetic vs control: ***Po0.0001,
**Po0.01, TK-null vs WT: nonsignificant.
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Figure 4 |Gene expression of ACE in kidney and lung of wild-
type (WT) and tissue kallikrein–deficient (TK-null) mice 1
month after induction of diabetes (series A). Black bars:
diabetic groups, white bars: control groups. Results are
means±s.e.m. n¼ 10–12/group. Results for each gene are
expressed relative to the mean of the corresponding WT control
group. Analysis of variance followed by Fisher PLSD post hoc test,
diabetic vs control: ***Po0.0001, TK-null vs WT: nonsignificant.
ACE, angiotensin I–converting enzyme.
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not invariably linked to albuminuria.28 During this early
phase of diabetic nephropathy glomerular hypertrophy was
present, but no glomerulosclerosis was observed, which
is consistent with the relative resistance of mouse strain
C57Bl/6J to renal lesions.28
These observations suggest that the higher albuminuria
observed in TK-null mice could arise from an increase in
glomerular permeability. As podocytes play a central role in
glomerular filtration barrier, we studied two physiologically
important components of these cells, nephrin and ezrin.
Nephrin is an essential component of the slit diaphragms
of the glomerulus. Gene expression of nephrin was shown
to decrease in the proteinuric phase but not in the early pre-
proteinuric phase in rats made diabetic by streptozotocin.29
Ezrin is concentrated along the apical membrane of the foot
processes of podocytes. It belongs to a family of plasma
membrane-cytoskeleton linking, actin-binding proteins that
have been identified as binding proteins for advanced
glycation end products,30 and implicated in diabetic
complications. Ezrin was also shown to be modulated during
podocyte injury and regeneration.31 In this study, we found
no change in nephrin gene expression in the entire kidney at
the early stage of diabetes. However, hypertrophy does not
develop in all glomeruli concurrently, and recent data suggest
that nephrin gene could be differentially expressed according
to glomerular size.32 A defect in ezrin mRNA level was
observed in this study in TK-deficient mice. This defect may
be indicative of podocyte dysfunction in these mice.
Kidney injury molecule (Kim-1), a type 1 transmembrane
glycoprotein, was shown to be markedly induced after
ischemia/reperfusion injury and exposure to nephrotoxi-
cants,33 in model of acute massive proteinuria34 and in non-
diabetic proteinuric patients.35 We show here for the first
time that Kim-1 is also associated with microalbuminuria in
diabetic nephropathy, thus extending the concept that Kim-1
is a biomarker not only for acute but also for chronic tubular
damage. The absence of genotype effect on Kim-1 expression
in diabetic mice may suggest that the difference of
albuminuria observed in absence and presence of TK was
not due to difference in proximal tubule damage.
Our data revealed gene and tissue- and time-specific effect
of diabetes on the expression of the KKS and renin–angio-
tensin system genes. To our knowledge, no study has
addressed mRNA quantification of components of both
peptide systems in major organs (the kidney, heart, lung, and
liver) during the hyperfiltrating phase of diabetes. The
present experiment is the first documenting the upregulation
of kallikrein–kinin system in the kidney at early stage of
diabetes, with increased gene expression of both factors
involved in kinin formation, TK and kininogen, and those
involved in kinin action, B1 and B2 receptor that is consistent
with increased availability of kinins, at least in some renal
compartments. The B1-R and B2-R gene expression was
increased by diabetes in both WT and TK-null mice, which
rules out the possibility of ligand-induced receptor upregula-
tion. This upregulation may be due to a direct effect of
hyperglycemia, as suggested by the effect of glucose on B1-R
and B2-R gene expression in cultured rat endothelial36 and
vascular smooth muscle cells.37 These observations suggest
that the nephroprotective role of TK in the context of
diabetes is mediated by kinins, although other non-kinin-
mediated actions of TK may also be involved.38,39
Concerning the renin–angiotensin system, angiotensino-
gen gene expression is increased in liver, kidney, and heart
and this can result in increased angiotensin II production.40
On the other hand, AT1-R mRNA is decreased. The decrease
in AT1-R mRNA may be secondary to elevated angiotensin II
concentration in the diabetic kidney, or reflect damage in the
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Figure 5 |Gene expression of the components of the renal
renin–angiotensin system in wild-type (WT) and tissue
kallikrein–deficient (TK-null) mice 1 month after induction of
diabetes (series A). Black bars: diabetic groups, white bars:
control groups. Results are means±s.e.m. n¼ 10–12/group.
Results for each gene are expressed relative to the mean of the
corresponding WT control group. Analysis of variance followed by
Fisher PLSD post hoc test, diabetic vs control: ***Po0.0001,
*Po0.05, TK-null vs WT; #Po0.05.
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Figure 6 |Gene expression of precursors of the kallikrein–kinin
and renin–angiotensin system in the liver of wild-type (WT)
and tissue kallikrein–deficient (TK-null) mice 1 month after
induction of diabetes (series A). Black bars: diabetic groups,
white bars: control groups. Results are means±s.e.m. n¼ 10–12/
group. Results for each gene are expressed relative to the mean of
the corresponding WT control group. Analysis of variance
followed by Fisher PLSD post hoc test, diabetic vs control:
***Po0.0001, *Po0.05, TK-null vs WT; nonsignificant.
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glomerulus and proximal tubule, the major site of AT1-R
synthesis.41 In any case these results document divergent
regulation of the two peptide systems at the receptor level,
presumably resulting in imbalance in their activity.
Angiotensin I-converting enzyme availability is a critical
factor for the activity of KKS and renin–angiotensin system,
especially in the renal circulation, which has very low level of
endothelial ACE.42 Diabetes induced a marked but transient
increase in ACE gene expression in the lung, an endothelium-
rich organ, but a decrease in the kidney. This is consistent
with previous findings.12 Induction of ACE gene expression
may also occur in endothelial cells of the kidney, contributing
to kinin depletion in the vascular compartment, but this
cannot be documented by mRNA measurement. Indeed, the
major site of ACE gene expression in the kidney is the
proximal tubule and renal ACE mRNA is mainly of tubular
origin. The diabetes-induced decrease in renal ACE mRNA is
indicative of tubular dysfunction,43,44 as also suggested by
induction of Kim-1 expression. Nevertheless, ACE produc-
tion by the endothelium is probably the most important
contributor to the deleterious effect of this enzyme on
diabetic nephropathy. There is some evidence that plasma
ACE circulating through the kidney, which originates from
endothelium, is increased in diabetes12 and locally produces
angiotensin II and metabolizes kinins.42 Moreover, neo-
expression of ACE by renal endothelial cells was observed in
diabetic kidney.45 All together, these observations are
consistent with increased availability of ACE in vascular
compartment in diabetes with deleterious consequences for
the kidney, and decreased availability of ACE in the tubular
compartment.
The pattern of KKS activation is not modified in TK-
deficient mice. However, AT2-R mRNA in the kidney was
slightly greater in control TK-null than WT mice, as
previously observed in carotid arteries.46 This may explain
the downregulation of renin gene expression in TK-deficient
mice (this study and Trabold et al.27) in agreement with the
hypothesis that AT2-R regulates renin–angiotensin system
activity by inhibition of renin synthesis.47 As the AT2
receptor is functionally coupled to TK,46,48 upregulation of
this receptor in TK-null mice may be an adaptative attempt
to counteract the lack of active KKS.
The contribution of kinins to the development of diabetic
nephropathy was assessed recently in two models of type 1
diabetes18,22 involving B2-R deletion. Kakoki et al.18 showed
that 6-month-old male Akita diabetic mice, with hypofiltrat-
ing kidney,49 developed overt albuminuria in the absence of
bradykinin B2 receptor, whereas WT diabetic littermates
remained microalbuminuric, suggesting a protective role of
KKS against the development of diabetic nephropathy. In
contrast, Tan et al.22 reported that deletion of B2 receptor
protects against microalbuminuria and the development of
diabetic nephropathy. The discrepancy between these studies
may be due, at least in part, to differences in genetic
background, extent of B1-receptor activation, and severity of
hyperglycemia. In the Tan et al. study, diabetic B2-null mice
developed, for unknown reasons, slightly lower hyperglyce-
mia level during the first 2 months than the WT mice.
Table 3 | Gene expression in wild-type and TK-null mice 2 months after induction of diabetes (series B)
Wild-type TK-null ANOVA (P-value)
CONT DIAB CONT DIAB Genotype Diabetes
Liver
Kininogen 1.00±0.10 1.39±0.28** 0.72±0.07 1.24±0.11** 0.24 0.017
Angiotensinogen 1.00±0.07 1.03±0.16 0.74±0.15 1.37±0.13** 0.76 0.016
Lung
ACE 1.00±0.16 0.96±0.21 0.85±0.14 1.24±0.15 0.82 0.16
Kidney
Kininogen 1.00±0.18 1.61±0.41 1.01±0.13 1.75±0.29** 0.77 0.022
B1 receptor 1.00±0.17 1.44±0.26 1.21±0.24 1.80±0.31* 0.25 0.04
B2 receptor 1.00±0.15 2.20±0.24*** 1.32±0.16 2.03±0.25 0.72 Po0.0001
TK 1.00±0.28 0.60±0.22 0±0 0±0 0.0003 0.31
ACE 1.00±0.11 0.47±0.11*** 0.93±0.08 0.75±0.04* 0.26 0.0006
Angiotensinogen 1.00±0.07 1.64±0.14*** 1.06±0.06 1.55±0.14 0.92 Po0.0001
AT1 receptor 1.00±0.21 0.66±0.15 1.05±0.08 0.48±0.07** 0.64 0.003
AT2 receptor 1.00±0.16 0.76±0.17 1.16±0.11 0.90±0.15 0.33 0.11
Renin 1.00±0.18 0.93±0.31 0.65±0.11 0.71±0.08 0.17 0.96
Nephrin 1.00±0.09 0.91±0.10 0.85±0.05 0.87±0.06 0.24 0.65
Ezrin 1.00±0.07 1.05±0.07 0.70±0.07 0.82±0.04 0.0003 0.21
Kim-1 1.00±0.21 65.0±13.2*** 0.80±0.16 57.8±9.1*** 0.65 0.0001
ACE, angiotensin-converting enzyme; ANOVA, analysis of variance; CONT, control groups; DIAB, diabetic groups; Kim-1, kidney injury molecule-1; TK-null, tissue
kallikrein–deficient mice.
Results are means±s.e.m., n=7–8/group.
Values for each gene are expressed relative to the mean of the corresponding wild-type control.
Fisher post hoc test: DIAB vs CONT, *Po0.05, **Po0.02, ***Po0.0001.
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Our study clarifies the issue by showing that for similar
levels of severe hyperglycemia, TK-null mice with drastically
reduced renal levels of kinins developed more severe
microalbuminuria than their WT littermates. One limitation
of the study relies on the fact that diabetic nephropathy
develops slowly in C57bl6 mice.28 After 2 months of diabetes,
mortality by metabolic complications increased sharply
(personal observation). This did not allow studying the
effect of TK deficiency on established diabetic nephropathy,
renal fibrosis, and glomerulosclerosis. Nevertheless, our
results support the concept that KKS has a net protective
effect at least in the early phase of diabetic nephropathy.
Albuminuria was also higher in diabetic mice with three
copies of the ACE gene than WT 4 weeks after diabetes
induction and worsened thereafter.12 This study suggests that
kinins deficiency is involved in the harmful impact of
genetically high ACE levels in the diabetic kidney, in both
mice and men. Genetic polymorphism of ACE levels is an
established risk factor for diabetic nephropathy.8–11 Partial
genetic TK deficiency occurs in man as a consequence of an
active site mutation (R53H) present in the heterozygote state
in 7% of white and 14% of black individuals.50 Carriers of the
R53H allele similar to those of the high ACE level allele may
be at increased risk of nephropathy in chronic hyperglycemia,
although this remains to be demonstrated in clinical studies.
MATERIALS AND METHODS
Animals
Two- to three-month-old female TK-null mice26 on C57Bl/6J
background, and their WT littermates were used. Four groups of
mice, WT control, WT diabetic, TK-null control, and TK-null
diabetic were studied. Diabetes was induced by 5–7 daily
intraperitoneal injections of low-dose of streptozotocin without
nephrotoxic effect (80 mg/g body weight).12 Control mice (CONT)
received vehicle (0.05mol/l sodium citrate, pH 4.5). Only diabetic
mice (DIAB) with hyperglycemiaX200mg per 100ml 10 days after
the first injection were included in the study. The mice were housed
with a 12 h light/dark cycle, and had free access to standard chow
(A03, Safe, Augy, France) and demineralized drinking water. Two
series of mice were studied, one was killed 5 weeks after diabetes
induction (series A, n¼ 10–12 mice/group) and the other at 9 weeks
(series B, n¼ 7–8 mice/group). A time point of 1 month diabetes
duration was chosen to examine the effects of TK on early changes in
diabetic kidney, without the potentially confounding effect of
hypertension or fibrosis. However, in a second study, mice were
followed for 2 months for studying the temporal effect of TK
deficiency during diabetes evolution. All experiments were con-
ducted in accordance with the European regulations for the care and
use of laboratory animals (L 358-86/609/EEC).
Functional study
Four weeks (series A and B) and 8 weeks (series B) after inducing
diabetes, 24 h urine collections were obtained from individual mice
that were housed temporarily in metabolic cages (Techniplast,
Limonest, France). Blood from the retro-orbital sinus was collected
at killing. Plasma and urine concentrations of sodium, potassium,
glucose, urea and creatinine were assayed with an automatic analyzer
(Konelab 20I, Orthoclinical Diagnostics, Thermo electron Corpora-
tion, Courtaboeuf, France). Urinary albumin concentration was
determined by immunonephelemetry (series A) (Behring laser-
nephelemeter, Marburg, Germany) or ELISA (series B) (Albuwell M,
Exocell, Philadelphia, PA). Urinary osmolality was measured using a
freezing point osmometer (Roebling, Germany). Urinary ketones and
pH were determined in spontaneously voided urine using the Keto-
Diabur-Test 5000 (Accu-Chek, Roche Diagnostic, Meylan, France) and
Duotest (Macherey-Nagel, Oensingen, Switzerland), respectively.
Blood b-hydroxybutyrate, the major blood ketone, was determined
with Optium Xceed (MediSense, ABOTT, Rungis, France). Urinary
kallikrein activity was measured by means of a chromogenic substrate
(S-226, Chromogenix, Biogenix, Maurin, France).
Blood pressure and heart rate were measured for 3 consecutive
days 4 and 8 weeks after inducing diabetes in conscious, restrained
mice by the tail-cuff method (BP-2000, Visitech system, Bioseb,
Vitrolles, France) (series B). Because subtle differences in blood
pressure may be missed by this technique, telemetric measurements
were performed before and after diabetes induction in another series
of mice (n¼ 4/group) equipped with TA11PA-C10 device (Data
Sciences International, St Paul, MN) as previously described.51
Heart and kidney histology and morphometry
One half of the right kidney and the heart were fixed in alcoholic
Bouin’s solution and 10% formaldehyde, respectively. Tissues were
embedded in paraffin. For the kidney, 4mm thick sections were
stained with Masson’s trichrome for qualitative assessment of
mesangium expansion and glomerular, tubulointerstitial and
vascular lesions, and with periodic acid-Schiff for morphometry.
Glomerular surface area was measured using computerized image
analysis as previously described.12 For the heart, a transversal section
just below mitral valve was stained with hematoxylin–eosin and
Sirius red for qualitative assessment of myocyte necrosis, myocardial
inflammation or fibrosis.
The remaining of the right kidney was used for electron
microscopy. The kidney was minced into 1mm3 pieces and was
fixed in 2.5% glutaraldehyde in phosphate buffer (pH 7.4, 0.1M),
postfixed in 2% OsO4 in phosphate buffer, dehydrated in graded
alcohol and embedded in Epon resin at 601C during 72 h. Ultra-thin
sections (52 nm) were stained with uranyl acetate and lead citrate
and examined under JEOL-100CXII transmission electron micro-
scopy (Jeol Ltd, Tokyo, Japan).
Quantification of mRNA abundance
Relative changes in gene expression of the renin–angiotensin system
and KKS components, and three genes coding for tubular or
structural glomerular proteins were quantified using real-time PCR.
Total RNA was isolated from the left kidney, heart apex, and pieces
of liver and lung (Qbiogen, MP Biomedicals, Illkirch, France).
cDNA was synthetized from 2 mg total RNA using 0.3 mg random
hexamers and 40U Superscript II MMLV-reverse transcriptase
(Invitrogen, Cergy Pontoise, France), in presence of 200U RNase-
OUT in a 20 ml final volume. Real-time PCR was performed on the
ABI PRISM 7000 Sequence Detection System by using TaqMan
Universal Master Mix and Assays-on-Demand Gene Expression
Probes for kallikrein, kininogen, kinin B1 (B1-R) and B2 (B2-R)
receptors, ACE, angiotensinogen, type 1 (AT1-R) and type 2
(AT2-R) angiotensin II receptors, renin, ezrin, nephrin, and kidney
injury molecule (Kim-1) (AppliedBiosystems, Applera France,
Courtaboeuf, France). Fifteen ng of reverse transcribed RNA was
submitted to PCR in a 20-ml final volume. Each sample was tested in
triplicate. DNA contamination was excluded by performing PCR
amplification without the reverse transcription step for each RNA
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sample, and blank without sample but with all reagents. Data were
normalized to 18S rRNA. Changes in the target gene relative to the
mean expression in the WT control group were calculated by the
2DDCT comparative method for each sample.52
Statistical analysis
Data are expressed as means±s.e.m. Statistical analyses were
performed using two-way analysis of variance followed, when
appropriate, by the Fisher protected least significant post hoc test.
Significance was set at Po0.05.
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